Jiho Han
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Jiho Han has a total of 94 co-authors. Here are the top co-authors by number of shared publications:
- Kiran K. Khush
Stanford University
3 shared publications Roy Lee
Department of Transplant, Stanford Health Care, Stanford, California
3 shared publicationsYoshifumi Naka
Division of Cardiac Surgery Department of Surgery Columbia University Medical Center New York New York
3 shared publicationsDarren Malinoski
Critical Care and Acute Care Surgery, Oregon Health Sciences University, Portland, Oregon
2 shared publicationsErik J. Henricksen
Department of Pharmacy, Stanford Health Care, Stanford, California
2 shared publications- Evan P. Kransdorf
Smidt Heart Institute, Cedars-Sinai Medical Center, Los Angeles, California, USA
2 shared publications
Latest Publications
- 16 November 2025
- Published by Elsevier in The Journal of Heart and Lung Transplantation
- Vol. 45 (3) , 378-385
Advanced hemodynamics for right ventricular failure: Evaluating the use of the myocardial performance score
- 16 November 2025
- Published by Elsevier in The Journal of Heart and Lung Transplantation
- Vol. 45 (3) , 378-385
Advanced hemodynamics for right ventricular failure: Evaluating the use of the myocardial performance score
- 6 March 2025
- Published by Elsevier in The Journal of Heart and Lung Transplantation
- Vol. 44 (7) , 1052-1062
Regional differences in primary graft dysfunction: A report from the international consortium on PGD
- 6 March 2025
- Published by Elsevier in The Journal of Heart and Lung Transplantation
- Vol. 44 (7) , 1052-1062
Regional differences in primary graft dysfunction: A report from the international consortium on PGD
- 5 October 2023
- Published by Elsevier in The Journal of Heart and Lung Transplantation
- Vol. 43 (3) , 387-393
HLA sensitization is associated with an increased risk of primary graft dysfunction after heart transplantation
- 5 October 2023
- Published by Elsevier in The Journal of Heart and Lung Transplantation
- Vol. 43 (3) , 387-393
HLA sensitization is associated with an increased risk of primary graft dysfunction after heart transplantation
- 5 January 2023
- Published by Elsevier in The Journal of Heart and Lung Transplantation
- Vol. 42 (5) , 617-626
Donor hyperoxia is a novel risk factor for severe cardiac primary graft dysfunction
- 5 January 2023
- Published by Elsevier in The Journal of Heart and Lung Transplantation
- Vol. 42 (5) , 617-626
Donor hyperoxia is a novel risk factor for severe cardiac primary graft dysfunction
- 1 February 2022
- Published by Elsevier in The Journal of Heart and Lung Transplantation
- Vol. 41 (2) , 237-243
Impact of using higher-risk donor hearts for candidates with pre-transplant mechanical circulatory support
- 1 February 2022
- Published by Elsevier in The Journal of Heart and Lung Transplantation
- Vol. 41 (2) , 237-243
Impact of using higher-risk donor hearts for candidates with pre-transplant mechanical circulatory support
- 14 August 2021
- Published by Wiley in Clinical Transplantation
- Vol. 35 (11) , e14460
Impact of diabetes mellitus on clinical outcomes after heart transplantation
Purpose: Diabetes mellitus (DM) is common among recipients of heart transplantation (HTx) but its impact on clinical outcomes is unclear. We evaluated the associations between pretransplant DM and posttransplant DM (PTDM) and outcomes among adults receiving HTx at a single center.Methods: We performed a retrospective study (range 01/2008 – 07/2018), n = 244. The primary outcome was survival; secondary outcomes included acute rejection, cardiac allograft vasculopathy, infection requiring hospitalization, macrovascular events, and dialysis initiation post‐transplant. Comparisons were performed using Kaplan‐Meier and multivariable Cox regression analyses.Results: Pretransplant DM was present in 75 (30.7%) patients and was associated with a higher risk for infection requiring hospitalization (p < 0.05), but not with survival or other outcomes. Among the 144 patients without pretransplant DM surviving to 1 year, 29 (20.1%) were diagnosed with PTDM at the 1‐year follow‐up. After multivariable adjustment, PTDM diagnosis at 1‐year remained associated with worse subsequent survival (hazard ratio 2.72, 95% confidence interval 1.03‐7.16). Predictors of PTDM at 1‐year included cytomegalovirus seropositivity and higher prednisone dose (> 5 mg/day) at 1‐year follow‐up.Conclusions: Compared to HTx recipients without baseline DM, those with baseline DM have a higher risk for infections requiring hospitalization, and those who develop DM after HTx have worse survival.
- 14 August 2021
- Published by Wiley in Clinical Transplantation
- Vol. 35 (11) , e14460
Impact of diabetes mellitus on clinical outcomes after heart transplantation
Purpose: Diabetes mellitus (DM) is common among recipients of heart transplantation (HTx) but its impact on clinical outcomes is unclear. We evaluated the associations between pretransplant DM and posttransplant DM (PTDM) and outcomes among adults receiving HTx at a single center.Methods: We performed a retrospective study (range 01/2008 – 07/2018), n = 244. The primary outcome was survival; secondary outcomes included acute rejection, cardiac allograft vasculopathy, infection requiring hospitalization, macrovascular events, and dialysis initiation post‐transplant. Comparisons were performed using Kaplan‐Meier and multivariable Cox regression analyses.Results: Pretransplant DM was present in 75 (30.7%) patients and was associated with a higher risk for infection requiring hospitalization (p < 0.05), but not with survival or other outcomes. Among the 144 patients without pretransplant DM surviving to 1 year, 29 (20.1%) were diagnosed with PTDM at the 1‐year follow‐up. After multivariable adjustment, PTDM diagnosis at 1‐year remained associated with worse subsequent survival (hazard ratio 2.72, 95% confidence interval 1.03‐7.16). Predictors of PTDM at 1‐year included cytomegalovirus seropositivity and higher prednisone dose (> 5 mg/day) at 1‐year follow‐up.Conclusions: Compared to HTx recipients without baseline DM, those with baseline DM have a higher risk for infections requiring hospitalization, and those who develop DM after HTx have worse survival.
- 29 January 2020
- Published by Wiley in Clinical Transplantation
- Vol. 34 (2) , e13779
Discontinuing amiodarone treatment prior to heart transplantation lowers incidence of severe primary graft dysfunction
Background: Recent studies have shown an increased incidence of primary graft dysfunction (PGD) in patients treated with amiodarone prior to orthotopic heart transplant (OHT). We hypothesized that discontinuation of amiodarone before OHT may lower the incidence of severe PGD.Methods: This was a single‐center retrospective study of 381 adult OHT recipients between January 2010 and June 2017. Within 6 months prior to OHT, 197 did not receive amiodarone (Group 1), 142 continued amiodarone to OHT (Group 2), and 42 had amiodarone treatment discontinued before OHT (Group 3).Results: 53 (13.9%) participants developed severe PGD, 13 (6.6%) of which were in Group 1, 36 (25.4%) were in Group 2, and 4 (9.5%) were in Group 3 (P < .001). Multivariable analysis revealed continued amiodarone treatment to OHT (Group 2; OR, 3.70; 95% CI, 1.26‐10.88; P = .018) to be an independent risk factor for the development of severe PGD when Group 1 served as the reference group. Moreover, patients in Group 3 had no difference in the risk of severe PGD (OR = 0.416, 95% CI = 0.08‐2.15; P = .296).Conclusion: We found that discontinuing amiodarone treatment prior to OHT resulted a lower incidence of severe PGD.
- 29 January 2020
- Published by Wiley in Clinical Transplantation
- Vol. 34 (2) , e13779
Discontinuing amiodarone treatment prior to heart transplantation lowers incidence of severe primary graft dysfunction
Background: Recent studies have shown an increased incidence of primary graft dysfunction (PGD) in patients treated with amiodarone prior to orthotopic heart transplant (OHT). We hypothesized that discontinuation of amiodarone before OHT may lower the incidence of severe PGD.Methods: This was a single‐center retrospective study of 381 adult OHT recipients between January 2010 and June 2017. Within 6 months prior to OHT, 197 did not receive amiodarone (Group 1), 142 continued amiodarone to OHT (Group 2), and 42 had amiodarone treatment discontinued before OHT (Group 3).Results: 53 (13.9%) participants developed severe PGD, 13 (6.6%) of which were in Group 1, 36 (25.4%) were in Group 2, and 4 (9.5%) were in Group 3 (P < .001). Multivariable analysis revealed continued amiodarone treatment to OHT (Group 2; OR, 3.70; 95% CI, 1.26‐10.88; P = .018) to be an independent risk factor for the development of severe PGD when Group 1 served as the reference group. Moreover, patients in Group 3 had no difference in the risk of severe PGD (OR = 0.416, 95% CI = 0.08‐2.15; P = .296).Conclusion: We found that discontinuing amiodarone treatment prior to OHT resulted a lower incidence of severe PGD.
- 1 September 2019
- Published by Elsevier in The Journal of Heart and Lung Transplantation
- Vol. 38 (9) , 930-938
Prognostic value of vasoactive-inotropic score following continuous flow left ventricular assist device implantation
- 1 September 2019
- Published by Elsevier in The Journal of Heart and Lung Transplantation
- Vol. 38 (9) , 930-938
Prognostic value of vasoactive-inotropic score following continuous flow left ventricular assist device implantation
- 1 November 2017
- Published by Elsevier in The Journal of Heart and Lung Transplantation
- Vol. 36 (11) , 1226-1233
Dose-dependent association between amiodarone and severe primary graft dysfunction in orthotopic heart transplantation
- 1 November 2017
- Published by Elsevier in The Journal of Heart and Lung Transplantation
- Vol. 36 (11) , 1226-1233
Dose-dependent association between amiodarone and severe primary graft dysfunction in orthotopic heart transplantation